[Evaluation of screening strategies of multidrug-resistant tuberculosis among pulmonary tuberculosis patients of the different risk levels]

Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Dec 10;42(12):2164-2169. doi: 10.3760/cma.j.cn112338-20210125-00063.
[Article in Chinese]

Abstract

Objective: To evaluate the detection of MDR-TB and XDR-TB patients and to provide evidence for further improvement of MDR-TB and XDR-TB screening strategy. Methods: Patients who were under drug resistance surveillance, registered and reported by the TB Management Information System of the Chinese Disease Prevention and Control Information System from 2012 to 2019 and resided in Guizhou province were retrospectively analyzed. The contribution of five high-risk subgroups to detection of MDR/XDR-TB were evaluated using population attributable risk proportion (PARP). Results: Of the 18 506 cases under drug resistance surveillance, patients who were male, aged between 25 and 54 years, with drug-resistant TB or with MDR/XDR-TB accounted for 68.65% (12 705/18 506), 47.69% (8 826/18 506), 15.90% (2 943/18 506) or 5.42% (1 003/18 506), respectively. Five high-risk subgroups made significant contributions to the detection of MDR/XDR-TB with a PARP of 57.00%. Specifically, the PARP were 21.70%, 19.49%, 11.90% and 2.30% for patients that were relapse and return, failed initial treatment, chronic/retreatment failure and smear-positive at the end of the second or third month, respectively. The detection rate of MDR/XDR-TB in high-risk groups was 15.89% (578/3 637) while in low-risk groups was 2.86% (425/14 869). Conclusions: Number of patients under drug resistance surveillance and the detection of MDR/XDR-TB trended to increase in Guizhou province from 2012 to 2019. The detection rate of MDR/XDR-TB in high-risk groups was higher than low-risk groups.

目的: 评价贵州省肺结核患者中的耐多药/广泛耐药结核病(MDR/XDR-TB)发现情况,为进一步优化筛查策略提供科学依据。 方法: 对贵州省2012-2019年中国疾病预防控制信息系统“结核病管理信息系统”登记报告的耐药监测肺结核病例进行回顾性分析,采用人群归因危险度百分比(PARP)评估不同耐药风险患者对MDR/XDR-TB发现的贡献。 结果: 在18 506例开展耐药筛查的病例中,男性占68.65%(12 705/18 506),25~54岁占47.69%(8 826/18 506),耐药患者占15.90%(2 943/18 506),MDR/XDR-TB占5.42%(1 003/18 506)。在发现的所有MDR/XDR-TB患者中,耐药高风险人群对病例发现的贡献占一半以上(PARP=57.00%),而不同类别的耐药高风险人群对MDR/XDR-TB发现的贡献不同,其中复发和返回、初治失败、慢性患者/复治失败和2/3个月末痰片涂阳的PARP分别为21.70%、19.49%、11.90%和2.30%。耐药高风险人群中MDR/XDR-TB检出率为15.89%(578/3 637),低风险人群中MDR/XDR-TB检出率为2.86%(425/14 869),差异有统计学意义(P<0.001)。 结论: 贵州省耐药监测力度及MDR/XDR-TB病例发现水平总体处于上升态势,耐药高风险人群中MDR/XDR-TB的检出率高于低风险人群。.

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Humans
  • Male
  • Mass Screening
  • Middle Aged
  • Mycobacterium tuberculosis*
  • Retrospective Studies
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / epidemiology
  • Tuberculosis, Pulmonary* / diagnosis
  • Tuberculosis, Pulmonary* / drug therapy
  • Tuberculosis, Pulmonary* / epidemiology

Substances

  • Antitubercular Agents